Shots:

• The companies enter into a supply agreement for Alemtuzumab to be used in Cellectis’ trials as a lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial to treat r/r ALL- and for UCART123 in AMELI-01 clinical trial to treat r/r AML but not for UCARTCS1 due to self-lymphodepleting activity
• Sanofi will provide alemtuzumab for Cellectis’ clinical trials and plans to execute the commercial supply of alemtuzumab under pre-agreed financial conditions
• Cellectis’ UCART22 and UCART123 candidate have the CD52 gene inactivated by TALENT gene-editing technology while Alemtuzumab is an anti-CD52 monoclonal Ab

  Ref: GLOBE NEWSWIRE | Image: Cellectis